Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor: University of Alabama at Birmingham
Study ID: NCT06289582
Phase: EARLY_PHASE1
Status: Recruiting

Apply to this trial

Conditions

Parkinson Disease

Eligibility Criteria

Sex: ALL
Age: 18 Years - 99 Years
Healthy Volunteers: Accepted

Interventions

[F-18]DPA714 administration IV — DRUG
brain PET/MRI imaging after \[F-18\]DPA-714 administration

Study Details

The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers. * To determine the longitudinal change in \[18F\]DPA-714 during a 24-month interval for prodromal and early initially untreated PD participants. Secondary Objectives * To evaluate the correlation between baseline \[18F\]DPA-714 and PPMI clinical and biomarker outcomes. * To evaluate the correlation between the longitudinal change of \[18F\]DPA-714 and PPMI clinical and biomarker outcomes * To acquire safety data following injection of \[18F\]DPA-714